polymorphisms within the investigated population was found to be in the expected range as reported in the literature, 3, 4 thus confirming that the sample was a reliable representation of the whole protocol study population. Unlike the results reported by Stanulla et al, 4 we did not find any correlation between the different GST(s) genotypes, prognostic factors and the relative risk of relapse. Treatment is not likely to play a role, being BFM and AIEOP ALL protocols very similar both in terms of treatment and overall results, at least since 1990. It should be emphasized that unlike the case-control methodology used in most of the studies reported so far, our study analyzed samples from a cohort of patients prospectively enrolled in a treatment protocol. This approach could reduce the limitations that hinder case-control studies.
TO THE EDITOR
We read with interest the recent article in which Paquette et al 1 evaluated the in vitro and in vivo ability of interferon-a (IFN-a) to induce dendritic cell (DC) differentiation in chronic myeloid leukemia (CML). We agree with their conclusion that the therapeutic activity of IFN-a in CML may be because of its ability to stimulate the generation of DCs that can present CML-specific antigens. We observed a lymphocytosis in bone marrow biopsy of three patients with CML in complete cytogenetic remission under IFN-a therapy, 2 years ago. 2 This prompted us to consider that IFN-a enhances the in vitro terminal differentiation of DCs and the recruitment of DCs of the immune system. 3 As B7-1 and B7-2 molecules, expressed by DCs, are essential for initiating antigenspecific T-cell responses, 4, 5 we evaluated their expression and the CD4/CD8 cell ratio in the peripheral blood of 15 patients with CML. These patients were treated following the guidelines criteria of the Italian Cooperative Study Group on CML. 6 In particular, 10 patients received IFN-a (9 million IU/daily) and five patients were treated with hydroxyurea (HU) at doses ranging between 1 and 2.5 g/daily.
Five out of 10 IFN-a-treated patients (group A) obtained a complete or major cytogenetic response within 9-18 months; this was maintained for a mean of 4.7 years (range 3-7). The other five patients treated with IFN-a (group B) for a mean of 1.6 years (range 1-2) or the five patients treated with HU (group C) for the same period of time, never achieved a cytogenetic response. Table 1 shows the results of the expression of surface marker molecules. Patients responsive to IFN-a showed a peculiar pattern of expression, with significant increase of B7-1 and B7-2 costimulatory molecules and CD8 lymphocytes. The percentage of expression of CD80 (1873.6) and CD86 (1472.7) molecules was significantly upregulated only in patients who achieved a complete or major In conclusion, our results further support the conclusion of Paquette et al that IFN-a stimulates DCs generation in CML, producing a T-cellmediated response through the induction of these specific costimulatory molecules. Ultimately, these studies provide an explanation of the mechanism of action of IFN-a in CML and stimulate studies of combination therapy with other agents in the treatment of CML. 
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